WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today
announced that the following presentations by Company management at
upcoming investor conferences will be webcast:
-
Jefferies 2013 Global Healthcare Conference
11:30 am ET,
June 5, 2013 in New York, NY
Presenter: Daniel Junius, President
and CEO
-
Goldman Sachs 34th Annual Global
Healthcare Conference
9:20 am PT, June 13, 2013 in Rancho
Palos Verdes, CA
Presenter: Gregory Perry, Executive Vice
President and CFO
The webcasts will be accessible live through the "Investor Information"
section of the Company's website, www.immunogen.com;
a replay will be available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
TAP technology uses a tumor-targeting monoclonal antibody to deliver one
of ImmunoGen's highly potent cancer cell-killing agents specifically to
tumor cells. Ten TAP compounds are now in the clinic, of which three are
wholly owned by the Company. The most advanced compound using
ImmunoGen's TAP technology, Kadcyla™, has been approved for marketing in
the US and Switzerland, and is undergoing regulatory review in the
European Union and Japan. Kadcyla is being commercialized in the US by
Genentech, a member of the Roche Group. More information about ImmunoGen
can be found at www.immunogen.com.
Kadcyla™ is a trademark of Genentech.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media